BACKGROUND: Antitumour necrosis factor (anti-TNF)-α therapy has made a significant impact on the treatment of psoriasis. Despite these agents being designed to neutralize TNF-α activity, their mechanism of action in the resolution of psoriasis remains unclear. OBJECTIVES: To understand better the mechanism of action of etanercept by examining very early changes in the lesional skin of patients with psoriasis responding to etanercept. METHODS: Twenty patients with chronic plaque psoriasis were enrolled and received etanercept 50 mg twice weekly. Skin biopsies were obtained before treatment and on days 1, 3, 7 and 14 post-treatment. Skin mRNA expression was analysed by quantitative reverse-transcription polymerase chain reaction and microarray; cytokine and phosphoprotein levels were assessed using multiplexed bead arrays. RESULTS: In etanercept responders, we observed no significant changes in interleukin (IL)-17A, IL-22 or interferon-γ mRNA or protein in the first week of treatment; however, there was a 2·5-fold downregulation of IL-17 receptor C (IL-17RC) mRNA (P < 0·05) after day 1, accompanied by decreased extracellular signal-regulated kinase-1/2 phosphorylation. Transcriptional analysis revealed that genes suppressed by etanercept significantly overlapped with IL-17A-induced genes, and a marked overlap was also observed between the genes suppressed by etanercept and by the anti-IL-17A agent ixekizumab. Finally we show that TNF-α enhances the expression of IL-17RC, and short hairpin RNA inhibition of IL-17R expression abrogates synergistic gene induction by TNF and IL-17A. CONCLUSIONS: These results suggest that the early responses of psoriasis plaques to etanercept may be due to decreased tissue responsiveness to IL-17A due to suppressed IL-17RC expression in keratinocytes, blunting the strong synergy between TNF-α and IL-17, which contributes to the maintenance of psoriasis lesions.
BACKGROUND: Antitumour necrosis factor (anti-TNF)-α therapy has made a significant impact on the treatment of psoriasis. Despite these agents being designed to neutralize TNF-α activity, their mechanism of action in the resolution of psoriasis remains unclear. OBJECTIVES: To understand better the mechanism of action of etanercept by examining very early changes in the lesional skin of patients with psoriasis responding to etanercept. METHODS: Twenty patients with chronic plaque psoriasis were enrolled and received etanercept 50 mg twice weekly. Skin biopsies were obtained before treatment and on days 1, 3, 7 and 14 post-treatment. Skin mRNA expression was analysed by quantitative reverse-transcription polymerase chain reaction and microarray; cytokine and phosphoprotein levels were assessed using multiplexed bead arrays. RESULTS: In etanercept responders, we observed no significant changes in interleukin (IL)-17A, IL-22 or interferon-γ mRNA or protein in the first week of treatment; however, there was a 2·5-fold downregulation of IL-17 receptor C (IL-17RC) mRNA (P < 0·05) after day 1, accompanied by decreased extracellular signal-regulated kinase-1/2 phosphorylation. Transcriptional analysis revealed that genes suppressed by etanercept significantly overlapped with IL-17A-induced genes, and a marked overlap was also observed between the genes suppressed by etanercept and by the anti-IL-17A agent ixekizumab. Finally we show that TNF-α enhances the expression of IL-17RC, and short hairpin RNA inhibition of IL-17R expression abrogates synergistic gene induction by TNF and IL-17A. CONCLUSIONS: These results suggest that the early responses of psoriasis plaques to etanercept may be due to decreased tissue responsiveness to IL-17A due to suppressed IL-17RC expression in keratinocytes, blunting the strong synergy between TNF-α and IL-17, which contributes to the maintenance of psoriasis lesions.
Authors: W-m Liu; R Mei; X Di; T B Ryder; E Hubbell; S Dee; T A Webster; C A Harrington; M-h Ho; J Baid; S P Smeekens Journal: Bioinformatics Date: 2002-12 Impact factor: 6.937
Authors: Andrew Johnston; Xianying Xing; William R Swindell; James Kochkodan; Marybeth Riblett; Rajan P Nair; Philip E Stuart; Jun Ding; John J Voorhees; James T Elder; Johann E Gudjonsson Journal: Hum Mol Genet Date: 2013-01-31 Impact factor: 6.150
Authors: Paul F Lizzul; Abhishek Aphale; Rama Malaviya; Yvonne Sun; Salman Masud; Viktor Dombrovskiy; Alice B Gottlieb Journal: J Invest Dermatol Date: 2005-06 Impact factor: 8.551
Authors: L W Moreland; M H Schiff; S W Baumgartner; E A Tindall; R M Fleischmann; K J Bulpitt; A L Weaver; E C Keystone; D E Furst; P J Mease; E M Ruderman; D A Horwitz; D G Arkfeld; L Garrison; D J Burge; C M Blosch; M L Lange; N D McDonnell; M E Weinblatt Journal: Ann Intern Med Date: 1999-03-16 Impact factor: 25.391
Authors: James G Krueger; Scott Fretzin; Mayte Suárez-Fariñas; Patrick A Haslett; Krista M Phipps; Gregory S Cameron; Juliet McColm; Artemis Katcherian; Inna Cueto; Traci White; Subhashis Banerjee; Robert W Hoffman Journal: J Allergy Clin Immunol Date: 2012-06-05 Impact factor: 10.793
Authors: Joseph F Fowler; Mei Sheng Duh; Ludmila Rovba; Sharon Buteau; Lisa Pinheiro; Francis Lobo; Jennifer Sung; Joseph J Doyle; Andrine Swensen; David A Mallett; George Kosicki Journal: J Am Acad Dermatol Date: 2008-11 Impact factor: 11.527
Authors: Lisa C Zaba; Irma Cardinale; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; Mayte Suárez Fariñas; Judilyn Fuentes-Duculan; Inna Novitskaya; Artemis Khatcherian; Mark J Bluth; Michelle A Lowes; James G Krueger Journal: J Exp Med Date: 2007-11-26 Impact factor: 14.307
Authors: Andrew Johnston; Xianying Xing; Liza Wolterink; Drew H Barnes; ZhiQiang Yin; Laura Reingold; J Michelle Kahlenberg; Paul W Harms; Johann E Gudjonsson Journal: J Allergy Clin Immunol Date: 2016-12-31 Impact factor: 10.793
Authors: William R Swindell; Xianying Xing; John J Voorhees; James T Elder; Andrew Johnston; Johann E Gudjonsson Journal: Physiol Genomics Date: 2014-05-20 Impact factor: 3.107
Authors: A Batalla; E Coto; J Gómez; N Eirís; D González-Fernández; C Gómez-De Castro; E Daudén; M Llamas-Velasco; R Prieto-Perez; F Abad-Santos; G Carretero; F S García; Y B Godoy; L F Cardo; B Alonso; S Iglesias; P Coto-Segura Journal: Pharmacogenomics J Date: 2016-09-27 Impact factor: 3.550
Authors: Viktor Todorović; Heath A McDonald; Paul Hoover; Joseph B Wetter; Anastasia E Marinopoulos; Clarissa L Woody; Loan Miller; Ariel Finkielsztein; Robert W Dunstan; Amy S Paller; Prisca Honore; Spiro Getsios; Victoria E Scott Journal: Exp Dermatol Date: 2022-03-07 Impact factor: 4.511
Authors: Amy C Foulkes; David S Watson; Daniel F Carr; John G Kenny; Timothy Slidel; Richard Parslew; Munir Pirmohamed; Simon Anders; Nick J Reynolds; Christopher E M Griffiths; Richard B Warren; Michael R Barnes Journal: J Invest Dermatol Date: 2018-07-17 Impact factor: 8.551
Authors: Alexander M Foster; Jaymie Baliwag; Cynthia S Chen; Andrew M Guzman; Stefan W Stoll; Johann E Gudjonsson; Nicole L Ward; Andrew Johnston Journal: J Immunol Date: 2014-05-14 Impact factor: 5.422